CLINICAL LABORATORY IMPROVEMENT AMENDMENTS (CLIA) ALTERNATE QUALITY ASSESSMENT SURVEY

According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0938-0650. The time required to complete this information collection is estimated to average 2.5 hours per response including the time to review instructions, search existing data sources, gather and maintain data needed, and complete and review the information collection. If you have any comments concerning the accuracy of the time estimate(s) or suggestions for improving this form, please write to: CMS, 7500 Security Boulevard, N2-14-26, Baltimore, Maryland 21244-1850.

GENERAL INFORMAT	ION: I	Please complet	te the following: (Pi	lease Print o	r Type)		
Laboratory Name			Name of Direct	or			
Laboratory Owner			Telephone Num	nber (include	area c	ode)	
Laboratory Address (No.,	Street)		Mailing Addres	Mailing Address (No., Street) (if different)			
City	State	Zip Code	City		State	Zip Code	
Type of CLIA Certificate	Curren	tly Held	Contact Person	in Laborato	ory		
Have any new testing sit certificate since the last (PLEASE UPDATE/CONNEL REPORT (CLIA). NEW DIRECTOR, TECHNUST BE RETURNED	CLIA su MPLET DOCU CHNICA	rvey? E THE ENC MENTATION AL SUPERVI	LOSED FORM C N TO SUPPORT T ISOR/CONSULTA	THE QUALI	FICAT	TIONS FOR ANY	
a) Has your laborator last inspection?	y added	l any new test	t(s) since your				
b) If yes, please list to TEST	est(s) th	•	added. FACTURER'S KI	T or EQUIF	PMENT	USED	
2. a) Has your laborator methods since you	-		in instruments or t	test			

b) If yes, please list the changes you have ma	ade.
volume (excluding waived, proficiency tests, questions of tests represented within each box. It	rrently performs. Indicate your current annual test uality control, calibration and calculated tests) for each not control in all test sites registered under the for guidance on how to determine test volumes.
Histocompatibility	Bacteriology
HLA Typing	Gram Stains
Other	Cultures
	Sensitivities
ANNUAL VOLUME:	Strep Screens
	Antigen Assays (chlamydia, etc.)
Syphilis Serology	H. Pylori
RPR	Other
FTA, MHA-TP	
Other	Mycobacteriology
	Acid Fast Smears
General Immunology	Mycobacterial Cultures
Mononucleosis Assays	Sensitivities
Rheumatoid Arthritis	Other
Febrile Agglutinins	
Cold Agglutinins	Mycology
HIV SS	Fungal Cultures
Antibody Assays (hepatitis, herpes, etc.)	- DTM
Mycoplasma Pneumoniae Assays	KOH Preps
ANA Assays	Other
Other	
	Parasitology
	Direct Preps
	Ova and Parasite Preps
	Wet Preps
	Other
	Virology-List all procedures performed
	below (RSV, HPV assays, cell cultures):
ANNUAL VOLUME:	ANNUAL VOLUME:

Chemistry **Routine Chemistry Urinalysis Toxicology** Albumin Automated urinalysis Acetaminophen ____ Urinalysis with microscopic analysis _____ Bilirubin, total ____ Blood alcohol Urine specific gravity by refractometer ____ Bilirubin, direct _ Carbamazephine ____ Urine specific gravity by urinometer ____ Calcium ____ Digoxin ____ Chloride Urine protein by sulfasalicylic acid Ethosuximide Cholesterol, total Other Gentamycin ____ CO2, total Lithium Creatinine **Endocrinology** Phenobarbitol $_{--}$ TSH ____ Phenytoin Glucose Free T4 Primidone ____ рН ____ pO2 ___ Total T4 ____ Procainamide ____ pCO2 ____ Triiodothyronine (T3) NAPA ____ Phosphorus ____ T3 Uptake ____ Quinidine Potassium PSA_ Salicylates ____ Serum beta-HCG _____ Protein, total _ Theophylline ____ Tobramycin ____ Cortisol Sodium ____ Triglycerides Other ____ Valproic acid ____ BUN Other ____ Uric acid ____ ALT/SGPT AST/SGOT ____ Gamma GGT ____ Alk phos

ANNUAL VOLUME FOR ALL CHEMISTRY TESTS:

____ Amylase

____ CKMB

____ Iron ____ LDH

CPK/CPK isoenzymes

HDL Cholesterol

LDH isoenzymes

____ Magnesium Ferritin

___ Folic acid Vitamin B12

Hematology	Immunohematology			
WBC count	ABO group			
RBC count	Rh(D) type			
Hemoglobin	Antibody screen			
Hematocrit (Other than spun micro)	Antibody identification			
Platelet	Compatibility testing			
Differential	Other			
MCV				
Activated clotting time				
Prothrombin time				
Partial thromboplastin time				
Fibrinogen	ANNUAL VOLUME:			
Reticulocyte count				
Manual WBC by hemocytometer				
Manual platelet by hemocytometer	Pathology			
Manual RBC by hemocytometer	Dermatopathology			
Sperm count	Oral pathology			
Other	PAP smear interpretation	ons		
	Other cytology tests			
	Histopathology			
	Other			
ANNUAL VOLUME:	ANNUAL VOLUME:			
Radiobioassay	Cytogenetics			
Red cell volume	Fragile X			
Schilling's test	Buccal smear			
Other	Other			
ANNUAL VOLUME:	ANNUAL VOLUME:			
TOTAL ANNUAL VOLUME FOR ALL T	ESTING PERFORMED:		-	
LABORATORY ASSESSMENT:		Yes	No	
PATIENT TEST MANAGEMENT				
4. Does your laboratory—				
a) review policies and procedures for spe preservation, and handling for comple	· · · · · · · · · · · · · · · · · · ·			
b) verify that these policies are available	e and followed?			
5. Does your laboratory—				
a) evaluate specimen processing for acc (e.g., specimen identification, tests or appropriate handling, and storage?	· ·			

		Yes	No	N/A
	b) review specimen rejection criteria and procedures for actions to be taken if criteria are met?			
	c) investigate the cause of the specimen rejection or other specimen processing problems and take action to prevent recurrences?			
6.	Does your laboratory review a number of test requisitions or patient medical charts to ensure—			
	a) completeness relevant to the testing performed and information requested?			
	b) information on the requisitions has been accurately transferred to the test report? (if a separate test requisition is used)			
	c) tests ordered were performed?			
	d) test results were reported to the authorized person?			
7.	Does your laboratory review—			
	a) a number of test reports or medical charts to ensure that test results from worksheets, instrument printouts or electronic transmissions were accurately reported?			
	b) its reporting system to ensure that panic values have been promptly brought to the attention of the authorized person?			
8.	Does your laboratory's process for reporting results include a mechanism to—			
	a) detect and document reporting errors?			
	b) prevent recurrences of reporting errors?			
	c) ensure that corrected reports are issued, documented and maintained?	•		
9.	Does your laboratory maintain and have the capability to retrieve—			
	a) patient test results or reports?			
	b) requisitions or test orders?			
	c) instrument printouts, work records, etc.?			
	d) quality control records, instrument maintenance records, corrective actions records?			
	OTE: A patient chart or medical record may meet the requirements test requisition, test record and test report.			
10.	Does your laboratory maintain records for a minimum of—			
	a) 2 years for test requisitions, worksheets, quality control and patient test reports?			
	b) 5 years for immunohematology (blood bank) records, quality control records and reports?			

		Yes	No	N/A
	c) 10 years for pathology reports?			
11.	Does your laboratory's specimen processing system allow your laboratory to track a specimen from collection to test reporting?			
QU	JALITY CONTROL (QC)			
12.	Are current written procedures available for each test the laboratory performs to ensure accurate and reliable test results including quality control, preventative maintenance, calibrations (if applicable), normal values and test reporting?			
ins of c spe	OTE: Manufacturers' package inserts are sufficient if the structions meet CLIA's requirements for frequency, number and type control material and, when applicable, they are supplemented wit exific instructions reflecting laboratory practice and are approved the current laboratory director.	h		
13.	Are all of your laboratory procedures current and approved by the present laboratory director?			
14.	Are all test modifications in practice in your laboratory included in the written test procedure and approved by the laboratory director?			
15.	For new tests or test systems added since the last CLIA survey, did your laboratory verify—			
	a) the accuracy of the method?			
	b) that the method met the manufacturer's performance specifications?			
16.	Does your laboratory follow manufacturers' instructions regarding operation, maintenance and test performance for instruments or test systems?			
17.	a) Does your laboratory routinely review a sample of records for all instruments requiring calibration to ensure that calibration and/or calibration verification is performed at least every 6 months?			
	b) Are calibrations performed in accordance with manufacturers' recommendations and/or in accordance with the laboratory's QC policies?			
	c) If calibration fails, does the laboratory follow its policy for corrective action and document it?			
18.	Does your laboratory review a sample of tests performed to ensure that			
	a) controls are run at the appropriate level and frequency as specified in the CLIA regulations?			

		Yes	No	N/A
	b) controls are within the acceptable range and met your criteria for acceptability?			
19.	Does your laboratory ensure that—			
	a) patient results are not reported when QC values fail to meet your criteria for acceptability?			
	b) your remedial and corrective action policies and procedures are followed?			
	c) your review of remedial and corrective actions are documented?			
	d) any ineffective policies and procedures are revised and approved by the laboratory director?			
PR	OFICIENCY TESTING (PT)			
20.	Is your laboratory continually enrolled in a CMS approved proficiency testing (PT) program(s), and performing PT for all regulated analytes tested in your laboratory? [see Appendix — for list of regulated PT analytes under CLIA]			
21.	Are PT samples tested in the same manner as patient samples, for example—			
	a) the same number of times?			
	b) using personnel who routinely perform testing?			
	c) using the laboratory's routine procedure for testing?			
	d) with routine workload?			
22.	In the past 2 years has your laboratory received a report of less than 100% for any PT results?			
	a) If yes, does your laboratory have a plan that includes a mechanism to conduct and document an investigation identifying the cause?			
	b) If yes, did your laboratory take and document corrective action(s) to avoid recurrence?			
	ease submit a copy of your laboratory's corrective action for a PT ent in which your laboratory did not receive 100%.			
23.	Does your laboratory review patient testing performed at the time of the PT testing event to determine any negative impact such testing errors had on the accuracy of patient testing?			
	a) Is corrective action taken?			

\mathbf{CO}	MPARISON OF TEST RESULTS	\mathbf{Yes}	No	N/A
24.	a) If your laboratory performs the same test by more than one method or instrument, is there a system that, twice a year, compares test results between the instruments or methods?			
	b) For tests where PT is not required or is not available, does your laboratory have a mechanism to verify and document, at least twice a year, that test results are accurate?			
RE	LATIONSHIP OF PATIENT INFORMATION TO TEST RESULTS			
25.	Does your laboratory have a mechanism to identify and evaluate patient test results that appear inconsistent with known patient data?			
PE	RSONNEL ASSESSMENT			
26.	Does your laboratory monitor and document employee competence, at least annually, for the tasks they perform?			
27.	Does your laboratory ensure that testing personnel have a working knowledge of and can perform new tasks required to obtain accurate and reliable test results?			
CO	MMUNICATIONS AND COMPLAINT INVESTIGATIONS			
28.	Does your laboratory have a system in place to monitor, document and resolve communication problems and complaints? (e.g., incorrect test(s) performed, patient name, test results, unacceptable specimens, etc.)			
29.	Does your laboratory have a system to monitor and document problems that may occur with the reference laboratory used, including specimen handling, test results and reporting?			
30.	Does your laboratory investigate complaints to determine the cause, take timely actions to remedy the problem and notify the appropriate people?			
QU	JALITY ASSURANCE (QA)			
31.	Does your laboratory—			
	a) have a mechanism to assess the findings of all quality assurance activities?			
	b) document problems identified and corrective actions taken during QA activities?			
	c) document communication of QA findings with staff (i.e., via memos, meeting agendas, meeting minutes, newsletters)?			
	d) assess whether the corrective actions taken to prevent recurrences are effective?			

		Yes	No
32.	Are all QA records maintained for a minimum of 2 years?		
PL	EASE NOTE:		
42	CFR 493.51		
	Notify HHS or its designee within 30 days of any changes in (1) ownersh (4) director or (5) technical supervisor.	•	
(b)	Notify HHS no later than 6 months after instituting any test or examina subspecialty area that is not included on the laboratory's certificate of compliance with requirements can be determined.		
(c)	Notify HHS no later than 6 months after any deletions or changes in test est or examination included in a specialty or subspecialty for which the issued a certificate of compliance.		_
AT	TESTATION:		
	test that I (or my designee) have truthfully completed and/or verify that tessment Survey accurately reflects the current operations of this laborate		ternate Quality
Sig	nature of Laboratory Director (sign in ink please) Date		
Tha	ank you for completing this form. We suggest that you make a copy of your s	ubmiss	ion for your records.
Coı	mments:		

AQAS CHECKLIST

SE RETURN THE FOLLOWING MATERIALS IN ONE ENVELOPE TO THE STATE AGENCY over letter for address) WITHIN 15 DAYS OF RECEIPT:
 THE COMPLETED, SIGNED AND DATED ALTERNATE QUALITY ASSESSMENT SURVEY (AQAS) FORM.
 PERSONNEL QUALIFICATIONS: Please submit a copy of the documentation demonstrating the qualifications of any new director, technical supervisor or clinical consultant WITH THE FORM CMS-209, Laboratory Personnel Report (CLIA).
 PT-RELATED CORRECTIVE ACTION(S): Please submit a copy of the laboratory's corrective action(s) as requested under question number 22.
 ATTESTATION: The AQAS form must be signed and dated by the laboratory director. (Page 9 of the AQAS)

Appendix A

PROFICIENCY TESTING (PT)

If you are performing testing for any of the analytes or tests listed below, you must be enrolled in PT for those analytes or tests:

Hematology:

Cell identification or white blood cell differential

Erythrocyte count

Hematocrit (excluding spun microhematocrit)

Hemoglobin (excluding HemaCue)

Leukocvte count

Platelet count

Fibrinogen

Partial thromboplastin time

Prothrombin time

Diagnostic Immunology

General Immunology

Alpha-1-antitrypsin

Alpha-fetoprotein (tumor marker)

Antinuclear antibody

Antistreptolysin O

Anti-human immunodeficiency virus (HIV)

Complement C3

Complement C4

Hepatitis markers (HBsAg, anti-HBc, HBeAg)

IgG

IgA

IgE IgM

Infectious mononucleosis Rheumatoid factor

Rubella

Syphilis Serology

Qualitative or quantitative

Chemistry

Routine Chemistry (serum, plasma or blood)

Alanine aminotransferase (ALT/SGPT)

Albumin

Alkaline phosphatase

Amylase

Aspartate aminotransferase (AST/SGOT)

Bilirubin, total

Blood gas (pH, pO2, and pCO2)

Calcium, total

Chloride

Cholesterol, total

Cholesterol, high density lipoprotein

Creatine kinase

Creatine kinase isoenzymes

Creatinine

Glucose (excluding measurements on devices cleared by FDA

specifically for home use)

Iron, total

Lactate dehydrogenase (LDH)

LDH isoenzymes

Magnesium

Potassium

Sodium

Total Protein

Triglycerides

Urea Nitrogen

Uric Acid

Chemistry

Endocrinology (serum, plasma, blood or urine)

Cortisol

Free Thyroxine

Human chorionic gonadotropin (excluding color comparison

tests for urine specimens)

T3 Uptake

Triiodothyronine

Thyroid Stimulating Hormone

Thyroxine

Chemistry

Toxicology

Alcohol (blood)

Blood lead

Carbamazepine

Digoxin

Ethosuximide

Gentamicin

Lithium

Phenobarbital

Phenytoin

Primidone

Procainamide (and metabolites)

Quinidine

Theophylline

Tobramycin

Valproic Acid

Immunohematology:

ABO group (excluding subgroups)

D(Rho) typing

Unexpected antibody detection

Compatibility testing

Antibody identification

Microbiology:

Bacteriology

Mycobacteriology

Mycology

Parasitology

Virology

Note: You must be enrolled in PT for the full extent of testing being performed (e.g., gram stain, acid fast stain, direct antigen testing, isolation, identification and susceptibility)

Appendix B

GUIDELINES FOR COUNTING TESTS

- For histocompatibility, each HLA typing (including disease associated antigens), HLA antibody screen, or HLA crossmatch is counted as one test.
- For microbiology, susceptibility testing is counted as one test per group of antibiotics used to determine sensitivity for one organism. Cultures are counted as one per specimen regardless of the extent of identification, number of organisms isolated and number of tests/procedures required for identification.
- Testing for allergens should be counted as one test per individual allergen.
- For chemistry profiles, each individual analyte is counted separately.
- For urinalysis, microscopic and macroscopic examinations, each count as one test. Macroscopics (dipsticks) are counted as one test regardless of the number of reagent pads on the strip.
- For complete blood counts, each **measured** individual analyte that is ordered **and reported** is counted separately. Differentials are counted as one test.
- Do not count calculations (i.e., A/G ratio, MCH, and T7), quality control, quality assurance and proficiency testing assays.
- For immunohematology each ABO, Rh, antibody screen, crossmatch or antibody identification is counted as one test.
- For histopathology, each block (not slide) is counted as one test. Autopsy services are not included. For those laboratories that perform special stains on histology slides, the test volume is determined by adding the number of special stains performed on slides to the total number of specimen blocks prepared by the laboratory.
- For cytology, each slide (not case) is counted as one test for both Pap smears and nongynecologic cytology.
- For cytogenetics, the number of tests is determined by the number of specimen types processed on each patient; i.e., a bone marrow and a venous blood specimen received on one patient is counted as two tests.